Having trouble accessing articles? Reset your cache.

Innate's TLR3 land grab

Innate Pharma S.A. says last week's deals with Schering-Plough Corp. and the Institut de Cancerologie Gustave Roussy give the company an opportunity to develop products in the toll-like receptor space, exploiting compounds where the mechanism of action already has been demonstrated. Two days after announcing the deals, the company proposed to go public on Euronext Paris(see "IPO Watch: Europe," A16).

Read the full 607 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers